The world’s first and only dual chamber leadless pacing system is now FDA approved: AVEIR DR from Abbott.¹ The following 3D animated video simulates implantation of both the right atrial and right ventricular devices in their respective heart chambers and retrieval of the right ventricular device.

This groundbreaking pacing technology features: ²
1. Beat-to-Beat Atrioventricular (AV) Synchrony made possible with industry-first, proprietary implant-to-implant (i2i) communication technology.
2. An Upgradeable System to tailor patient therapy over time by giving physicians the option to add a device and upgrade to dual chamber as needed.
3. Long-term Device Retrieval, with a success rate above 88% for AVEIR VR’s predicate device through 9 years regardless of implant duration. ³

AVEIR DR offers the same clinical benefits of traditional dual chamber pacemakers but without the associated lead and pocket-related complications including infection, lead fracture, lead insulation problems, skin erosion, keloid formation and no visible scarring or movement restrictions. ⁴ ⁵

Discover the leadless advantage today.

To learn more, visit: AVEIR DR Dual Chamber Leadless Pacemaker System | Abbott ([ Ссылка ])

To view important safety information, visit: AVEIR DR Important Safety Information | Abbott ([ Ссылка ])

References:
1. AVEIR DR FDA Approval
2. AVEIR Leadless Pacemakers and Delivery Catheter IFU, ARTEN600284235.
3. Reddy, VY, et al. Worldwide Experience with Leadless Pacemaker Retrievals: A Worldwide Nanostim Experience out of 9y. Presented at: APHRS 2022; Nov 18-20, 2022; Singapore.
4. Sattar et al. Complications of leadless vs conventional (lead) artificial pacemakers - a retrospective review. Journal of community hospital internal medicine perspectives vol. 10,4 328-333. 2 Aug. 2020, doi:10.1080/20009666.2020.1786901
5. Reddy VY, Cantillon DJ, John IP. San Francisco, CA: 6 May 2016. A comparative study of acute and mid-term complications of leadless vs transvenous pacemakers. Late-Breaking Clinical Trials II. Presented at Heart Rhythm Society 2016; pp. 02–04. Abstract LBCT. MAT-2307648 v1.0 | Item approved for U.S. use

MAT-2308923 v1.0| Item approved for U.S. use

свернуть